Literature DB >> 7513139

Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470).

T Yamamoto1, K Sudo, T Fujita.   

Abstract

Growth inhibition of tumor cells and vascular endothelial cells in M5076 tumors was examined following treatment with TNP-470 to elucidate its antitumor action. The bromodeoxyuridine-labeling index (LI) of tumor and endothelial cells was significantly decreased by TNP-470 treatment to 47 and 9% of the controls, respectively. The LI of endothelial cells was decreased earlier and more extensively than that of tumor cells. In contrast, the LI of endothelial cells was not decreased by treatment with chemotherapeutic agents, adriamycin and cisplatin, at the dose giving a similar growth inhibition on tumor cells. These results suggest that the antitumor action of TNP-470 is exerted by its angiogenesis inhibition.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513139

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  17 in total

1.  Angiogenesis Inhibitor O-(Chloroacetyl-carbamoyl) fumagillol (TNP-470) Inhibits Tumor Angiogenesis, Growth and Spontaneous Metastasis of MKL-4 Human Breast Cancer Cells in Female Athymic Nude Mice.

Authors: 
Journal:  Breast Cancer       Date:  1994-12-30       Impact factor: 4.239

2.  Protein N-terminal processing: substrate specificity of Escherichia coli and human methionine aminopeptidases.

Authors:  Qing Xiao; Feiran Zhang; Benjamin A Nacev; Jun O Liu; Dehua Pei
Journal:  Biochemistry       Date:  2010-07-06       Impact factor: 3.162

3.  Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine.

Authors:  Xue-fen Wang; Ling-fang Tu; Li-hong Wang; Jian-ying Zhou
Journal:  J Zhejiang Univ Sci B       Date:  2006-10       Impact factor: 3.066

4.  Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.

Authors:  Y Kakeji; B A Teicher
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

5.  Structure of the angiogenesis inhibitor ovalicin bound to its noncognate target, human Type 1 methionine aminopeptidase.

Authors:  Anthony Addlagatta; Brian W Matthews
Journal:  Protein Sci       Date:  2006-07-05       Impact factor: 6.725

Review 6.  The influence of angiogenesis research on management of patients with breast cancer.

Authors:  J Folkman
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

7.  The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice.

Authors:  H J Bernsen; P F Rijken; H Peters; H Bakker; A J van der Kogel
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

8.  Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1.

Authors:  Y Zhang; E C Griffith; J Sage; T Jacks; J O Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

9.  Antitumor effect of TNP-470 is not associated to decrease of angiogenesis in an experimental malignant neuroectodermic tumor.

Authors:  C Morales; M Zurita; J Vaquero
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

10.  Inhibition of tumor growth and microvascular angiogenesis by the potent angiogenesis inhibitor, TNP-470, in rats.

Authors:  M Niwano; S Arii; A Mori; S Ishigami; T Harada; M Mise; M Furutani; M Fujioka; M Imamura
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.